ANXA2 was reported to activate AKT/GSK3β and AKT/mTOR signaling in gastric, breast, and colorectal cancer [42–44], whereas ANXA2 is a substrate of ITSN1-L-mediated cell–substrate adhesion through the FAK/integrin β3 pathway [45]. Here, ANXA2 is linked to colorectal cancer.